Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture
- PMID: 22890552
- DOI: 10.1038/labinvest.2012.103
Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture
Abstract
Non-alcoholic fatty liver disease can progress to steatohepatitis and fibrosis, and is also associated with impaired liver regeneration. The pathophysiology remains elusive. We recently showed that severe steatosis is associated with an increase in portal pressure, suggesting liver flow impairment. The objective of this study is to directly assess total intrahepatic resistance and its potential functional and structural determinants in an in situ perfusion model. Male Wistar rats fed a control (n = 30) or a methionine-choline-deficient (MCD) diet (n = 30) for 4 weeks were compared. Liver tissue and serum analysis, in vivo haemodynamic measurements, in situ perfusion experiments and vascular corrosion casts were performed. The MCD group showed severe steatosis without inflammation or fibrosis on histology. Serum levels and liver tissue gene expression of interleukin (IL)-6, tumour necrosis factor-α, IL-1β and interferon-γ, liver tissue myeloperoxidase activity and liver immunohistochemistry with anti-CD68 and anti-α smooth muscle actin were comparable between groups, excluding significant inflammation. Flow-pressure curves were significantly different between groups for all flows (slope values: 0.1636 ± 0.0605 mm Hg/ml/min in controls vs 0.7270 ± 0.0408 mm Hg/ml/min in MCD-fed rats, P < 0.001), indicating an increased intrahepatic resistance, which was haemodynamically significant (portocaval pressure gradient 2.2 ± 1.1 vs 8.2 ± 1.3 mm Hg in controls vs MCD, P<0.001). Dose-response curves to acetylcholine were significantly reduced in MCD-fed rats (P < 0.001) as was the responsiveness to methoxamine (P<0.001). Vascular corrosion casts showed a replacement of the regular sinusoidal anatomy by a disorganized pattern with multiple interconnections and vascular extensions. Liver phosphorylated endothelial NO synthase (eNOS)/eNOS and serum nitrite/nitrate were not increased in severe steatosis, whereas liver thromboxane synthase expression, liver endothelin-1 (ET-1) expression and serum andothelin-1 concentration were significantly increased. Severe steatosis induces a haemodynamically significant increase in intrahepatic resistance, which precedes inflammation and fibrogenesis. Both functional (endothelial dysfunction and increased thromboxane and ET-1 synthesis) and structural factors are involved. This phenomenon might significantly contribute to steatosis-related disease.
Similar articles
-
Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD.JHEP Rep. 2021 Nov 25;4(2):100412. doi: 10.1016/j.jhepr.2021.100412. eCollection 2022 Feb. JHEP Rep. 2021. PMID: 35036886 Free PMC article.
-
Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats.Lab Invest. 2018 Oct;98(10):1263-1275. doi: 10.1038/s41374-017-0018-z. Epub 2018 Jan 11. Lab Invest. 2018. PMID: 29326427
-
Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.Gastroenterology. 2007 Feb;132(2):709-19. doi: 10.1053/j.gastro.2006.12.041. Epub 2006 Dec 20. Gastroenterology. 2007. PMID: 17258737
-
Hemodynamics in the isolated cirrhotic liver.J Clin Gastroenterol. 2007 Nov-Dec;41 Suppl 3:S254-8. doi: 10.1097/MCG.0b013e318150d3b5. J Clin Gastroenterol. 2007. PMID: 17975473 Review.
-
Endothelial dysfunction in the regulation of cirrhosis and portal hypertension.Liver Int. 2012 Feb;32(2):199-213. doi: 10.1111/j.1478-3231.2011.02579.x. Epub 2011 Jul 5. Liver Int. 2012. PMID: 21745318 Free PMC article. Review.
Cited by
-
The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease.Eur Cardiol. 2014 Jul;9(1):10-15. doi: 10.15420/ecr.2014.9.1.10. Eur Cardiol. 2014. PMID: 30310479 Free PMC article. Review.
-
The impact of hepatic steatosis on portal hypertension.PLoS One. 2019 Nov 6;14(11):e0224506. doi: 10.1371/journal.pone.0224506. eCollection 2019. PLoS One. 2019. PMID: 31693695 Free PMC article.
-
Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD.JHEP Rep. 2021 Nov 25;4(2):100412. doi: 10.1016/j.jhepr.2021.100412. eCollection 2022 Feb. JHEP Rep. 2021. PMID: 35036886 Free PMC article.
-
Portal Hypertension in Nonalcoholic Fatty Liver Disease: Challenges and Paradigms.J Clin Transl Hepatol. 2023 Oct 28;11(5):1201-1211. doi: 10.14218/JCTH.2023.00029. Epub 2023 May 31. J Clin Transl Hepatol. 2023. PMID: 37577237 Free PMC article. Review.
-
Intrahepatic vascular changes in non-alcoholic fatty liver disease: Potential role of insulin-resistance and endothelial dysfunction.World J Gastroenterol. 2017 Oct 7;23(37):6777-6787. doi: 10.3748/wjg.v23.i37.6777. World J Gastroenterol. 2017. PMID: 29085222 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials